161 related articles for article (PubMed ID: 31822201)
1. Pomalidomide desensitization for hypersensitivity: A case report.
Park JJ; Huang E; Monteleone CA; Kane MP; Cooper DL
J Oncol Pharm Pract; 2020 Jul; 26(5):1244-1247. PubMed ID: 31822201
[TBL] [Abstract][Full Text] [Related]
2. Desensitization to thalidomide in a patient with multiple myeloma.
Nucera E; Schiavino D; Hohaus S; Leone G; Buonomo A; Lombardo C; Patriarca G
Clin Lymphoma Myeloma; 2008 Jun; 8(3):176-8. PubMed ID: 18650182
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
4. Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs.
Grandoni F; Stalder G; Borgeat Kaeser A; Ribi C; Cairoli A; Blum S
Leuk Lymphoma; 2019 Dec; 60(12):3087-3089. PubMed ID: 31161829
[No Abstract] [Full Text] [Related]
5. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
6. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Seki JT; Banglawala S; Lentz EM; Reece DE
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
[No Abstract] [Full Text] [Related]
7. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
8. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
9. [Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization].
Hagihara M; Ide S; Ohara S; Uchida T; Inoue M; Hua J
Rinsho Ketsueki; 2019; 60(2):137-139. PubMed ID: 30842382
[TBL] [Abstract][Full Text] [Related]
10. Pomalidomide for the management of refractory multiple myeloma.
Summers BB; Cole SW; Olin JL
Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
[TBL] [Abstract][Full Text] [Related]
11. Allergic reaction to fluorescein dye: successful one-day desensitization.
Knowles SR; Weber EA; Berbrayer CS
Can J Ophthalmol; 2007 Apr; 42(2):329-30. PubMed ID: 17392867
[TBL] [Abstract][Full Text] [Related]
12. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
13. Successful desensitization in a patient with lenalidomide hypersensitivity.
Phillips J; Kujawa J; Davis-Lorton M; Hindenburg A
Am J Hematol; 2007 Nov; 82(11):1030. PubMed ID: 17617781
[No Abstract] [Full Text] [Related]
14. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Li Y; Kassir N; Wang X; Palmisano M; Zhou S
J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381
[TBL] [Abstract][Full Text] [Related]
15. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
[TBL] [Abstract][Full Text] [Related]
17. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Yau P; Jimenez-Zepeda VH; Bailey K; Duggan P; Tay J; Bahlis NJ; Neri P; McCulloch S
Leuk Lymphoma; 2019 Dec; 60(13):3199-3203. PubMed ID: 31190585
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
19. Case of angioedema and urticaria induced by lenalidomide.
Uchiyama A; Motegi S; Yamada K; Uehara A; Ishikawa O
J Dermatol; 2014 Feb; 41(2):179-81. PubMed ID: 24387621
[No Abstract] [Full Text] [Related]
20. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
